Transcript: Nano X Imaging Q4 2025 Earnings Conference Call – Nano X Imaging (NASDAQ:NNOX)

Women and gents, thanks for standing by. Welcome to the Nano X Imaging fourth quarter 2025 earnings name. Right now, all contributors are in a hear solely mode. After the speaker’s presentation, there will probably be a query and reply session. To ask a query throughout the session, you would want to press star 11 in your phone. You’ll then hear an automatic message advising that your hand is raised. And to withdraw your query, please press Star one one once more. Please be suggested that immediately’s convention is being recorded. I would love now to show the convention over to Mike Cavanaugh, Investor Relations. Please go forward.

Good morning and welcome to the Nano X Imaging fourth quarter 2025 investor name. Earlier immediately, Nano X Imaging Restricted launched monetary outcomes for the quarter ending December 31, 2025. The discharge is presently out there on the Traders part of the Firm’s web site. With me immediately are Erez Meltzer, Chief Govt Officer and Performing Chairman, and Ron Daniel, Chief Monetary Officer. Earlier than we get began, I wish to remind everybody that administration will probably be making statements throughout this name that embrace ahead trying statements concerning the Firm’s monetary outcomes, analysis and improvement, manufacturing and commercialization actions, regulatory course of and medical actions, amongst different issues. These statements are topic to dangers, uncertainties and assumptions which are primarily based on administration’s present expectations as of immediately and will not be up to date sooner or later. Due to this fact, these statements shouldn’t be relied upon as representing the corporate’s views as of any subsequent date. Elements that will trigger such a distinction embrace, however should not restricted to, these described within the Firm’s filings with the securities and Trade Fee. We can even consult with sure non GAAP monetary measures to supply extra data to traders. A reconciliation of the non GAAP to GAAP measures is supplied with our press launch, with the first variations being non GAAP internet loss attributable to strange shares, non GAAP price of income, non GAAP gross revenue, non GAAP gross revenue margin, non GAAP analysis and improvement bills, non GAAP gross sales and advertising and marketing bills, non GAAP common and administrative bills, and non GAAP gross loss per share. With that, I would now like to show the decision over to Erez Meltzer.

Thanks, Mike, and thanks all for becoming a member of us immediately. Within the fourth quarter of 2025, we continued to maneuver the enterprise ahead throughout a number of fronts. Whereas our main focus stays on increasing our business presence. Given the present geopolitical scenario, we spent a variety of effort throughout the quarter and the start of 2026 to safe our provide chain and strengthen our monetary positions as effectively. On prime of that, we made good progress advancing the capabilities of Nano X’s platform and strengthening the operational infrastructure wanted to help our long run development. I am blissful to report that we not too long ago entered into an settlement with Howard Know-how Options, a division of Howard Industries, which has a nationwide attain and a longtime presence in healthcare and public sector markets, offering us with a scalable framework for increasing nanox ARC deployment. This settlement displays our confidence within the business demand for the Nano X ARC and our skill to have interaction companions that may help sustained development in system placement throughout the US below the framework of this settlement, Howard is predicted to deploy 300 Nanox arc techniques over a 3 years interval, of which 60 are indicated to be deployed within the first 12 months. We additionally not too long ago introduced a number of business agreements which collectively accumulates to roughly 360 techniques over a two to a few years interval. These partnerships broaden our attain throughout imaging facilities and specialty care settings the place level of care imaging is integral to medical workflow and affected person administration. This represents a elementary shift in how we’re poised to scale our enterprise from offering our expertise to deploying in a significant quantity, shifting towards a rising CAPEX portion. That is what we see as getting us nearer to our indicated income of 2026. The framework has the potential to grow to be a significant contributor over time and offers us confidence in our skill to transform our sturdy pipeline into income as we transfer ahead. We view this as continued momentum and see ourselves transferring nearer to an inflection level. We noticed a transparent shift out there notion at main radiology conferences together with RSNA within the US and ECR in Europe, the place engagement and inbound curiosity elevated meaningfully. We’ve additionally taken vital steps to strengthen our operational basis. A key element of this initiative is the restructuring of sure actions in our Korean manufacturing facility with the intention to cut back our Korean operation, OPEX and money burn and enhance effectivity whereas sustaining our provide of nanox ARC system parts. We’re very happy with the progress we have now made not too long ago, however it’s clear that the tempo of deployment continues to be influenced by varied exterior processes together with import licenses, building timelines and regulatory necessities in sure markets. These steps take time to finish and whereas we’re not setting time with the tempo and wish to see deployments extra sooner, this displays the present working actuality throughout a number of markets. We count on that many of those processes will probably be streamlined as extra websites transfer by way of the pipeline. Introducing new expertise of any variety right into a medical atmosphere is all the time complicated course of. It requires alignment throughout medical workflow, regulatory framework and operational infrastructure in addition to altering behaviors which all takes time to realize. Whereas this may decelerate the early levels of deployment, it is usually a pure a part of introducing progressive expertise into the healthcare techniques. Turning to revenues, we proceed to focus on $35 million in income for the total 12 months of 2026 primarily based on the execution of our present plans. At this time, as a part of the above talked about, we have now signed business settlement which we imagine might end in current and future placements of about 400 techniques globally over the following 23 years. Of this, roughly 38 techniques are presently at varied levels of deployment, together with demonstration, business set up and techniques pending building and or regulatory approval. As well as, There are roughly 15 techniques which are anticipated to be put in over the following few months as a part of our NAS imaging community. That mentioned, it is very important emphasize that our present income base stays at an early stage and a part of this deploy base is just not producing revenues and the tempo of REMPROP will rely totally on on the timing of system activation, their transition right into a income producing operation and the influence of the deployment by the enterprise companions. As extra techniques transfer into operation and utilization will increase, we count on income to construct accordingly. Nevertheless, the precise timing of this development might fluctuate and all the time relying on the deployment course of and progress and our elements. I’ll now present some extra colour on the Korea restructuring that I referenced in my opening remarks. Just lately we adopted a restructuring plan designed to higher align our manufacturing price construction with our long run monetary mannequin, help our path towards improved gross margin and align our manufacturing capabilities with the corporate’s strategic priorities. As a part of this plan and our broader price discount efforts, we’re closing our chip manufacturing line in South Korea, downsizing our fabrication services and shifting manufacturing to established worldwide manufacturing companions together with sisam, a Switzerland primarily based manufacturing accomplice. We presently maintain substantial beginner stock which we plan to work by way of as we transition to a extra environment friendly outsourced manufacturing mannequin higher aligned with present and projected demand. With these actions, we count on to cut back structural and overhead prices, decrease our money burn and improve general operation effectivity. With that overview, let’s now take an in depth have a look at at our varied enterprise segments beginning with the US Deployment. Past the {hardware} settlement, we additionally not too long ago introduced a distribution settlement with Imperial Imaging Know-how, a US primarily based supplier of diagnostic imaging resolution, to help rollout throughout the Southeast, significantly in orthopedic targeted atmosphere the place there may be sturdy demand for a degree of care imaging. As well as, we signed agreements with distributors akin to Integrity Imaging, a US primarily based supplier of medical imaging options with established relationship throughout imaging facilities and healthcare suppliers Elite Surgical, which serves surgical and specialty care environments Digital X Ray Imaging, a number one diagnostic imaging supplier with deep regional current throughout Arkansas and most not too long ago a collaboration with Nu dx, an imaging resolution supplier targeted on increasing entry to diagnostic imaging and radiology oncology system to help all to help the deployment of nanox ARC techniques, these collaborations purpose to strengthen our distribution capabilities by including gross sales assets and on the bottom current expands our geographic protection and we imagine it’s the potential to grow to be a significant contributor to revenues over time. In parallel, we stay in lively dialogue with extra companions reflecting continued curiosity from medical tools suppliers and sure additional enlargement of our U.S. pipeline. Alongside our channel technique, our U.S. direct gross sales workforce on the bottom continues to make progress in focused medical segments. For instance, we not too long ago signed an settlement with Regional Sports activities Drugs in Orthopedic Group, our first orthopedic observe buyer in the US. This represents an vital step right into a phase the place imaging performs a central function in diagnostic and remedy choices and the place suppliers profit from having imaging out there on website. Orthopedics stay a excessive quantity and imaging pushed specialty with a robust incentives to retain imaging in home. Moreover, we’re advancing the nanox Imaging Community, a targeted initiative designed to construct a community primarily based imaging companies mannequin within the US this initiative targets segments akin to the employees compensation and specialised care reimbursement dynamics might help greater per scan pricing. We’re presently deploying already techniques throughout quite a few websites within the U.S. below this mannequin, Nanox help Nanox arc system deployment, upkeep and connectivity whereas our companions handle website operation and native engagement. Whereas nonetheless within the very early stage, we imagine this initiative can grow to be an vital element of our long run business technique as utilization will increase and the mannequin is additional validated. To offer extra context round this shift in engagement, had been participated in two main trade occasions throughout the interval at RSNA, the world’s largest annual radiology convention held within the U.S. our sales space that includes reside demonstration of the NanoPSR system noticed sturdy curiosity all through the occasion on the European Congress of Radiology, the biggest radiology convention in Europe, we showedcases the nanox ARC reside in Europe for the primary time and introduced new medical and AI information. Engagement ranges had been excessive, reflecting rising consciousness of the system’s medical worth and its potential function in routine imaging workflow. We had been additionally proud to obtain the Pink Dot award for product design 226 for the Nanox ArcX prestigious worldwide recognition that displays the maturity, usability and medical readiness of our platform. Let’s now flip to work outdoors of the U.S. as I discussed earlier concerning ECR, we had been additionally honored to obtain the Newcomer Award at ECR226 reflecting the rising recognition of NanoX throughout the European radiology neighborhood. In February, NanoX introduced an unique distribution settlement with Inter SRL a number one medical distributor in Argentina with greater than 35 years of expertise. Below this settlement, Intech will oversee advertising and marketing, distribution, set up and help for the nanox ARC system and associated companies throughout the nation. The collaboration meant to help business enlargement of Nanop’s 3D digital tomosynthesis expertise in Argentina and strengthen the corporate’s presence in Latin America. Leveraging InTech’s established relationship with healthcare suppliers and nationwide broad service capabilities, Commercialization will probably be topic to acquiring the required regulatory approval in Latin America. We had been anticipated for a big presentation on the Worldwide Congress of Radiology, the ICR in Cartagena, Colombia. The presentation would help medical dialogue round digital tomosynthesis and contribute to engagement with regional clinicians trade stakeholders in Europe. We proceed to construct momentum by way of companions and extra regional distributors. As a reminder, over the previous few quarters we have now introduced a number of European collaborations together with France, Romania, Czech Republic, Serbia, alongside extra engagements in different European markets. These collaborations help our skill to navigate native regulatory environments and advance commercialization throughout a number of international locations. Switching gears, we proceed to advance the regulatory work that helps our business initiatives by increasing the use instances for our options and making them accessible in additional markets. We’ve superior key milestones together with Faucet 2D clearance in the US. As a reminder, Faucet 2D is a 2D view picture output for the NanoSarc system, a sensible device for geologists to reinforce their diagnostic confidence as they grow to be extra skilled evaluating digital tomosynthesis pictures. In a part of our broader imaginative and prescient to alleviate adjunctive use limitations over time, we additionally up to date the AMAR approval for nanox AR in Israel primarily based on our present CE mark, enabling use of the techniques with out adjunct limitation. Elimination of the adjunct use limitation within the US Stay a key regulatory precedence. We imagine this is a vital step that may broaden our addressable market and help broader adoption. We’re additionally working to finalize our STEM ART submission for the NanOps ARC in Europe, which is presently anticipated in 2026. Topic to vary primarily based on regulatory priorities Turning to our AI enterprise, we proceed to strengthen our place as a complete platform for the interpretation of medical pictures. I am blissful to report that Cedars Sinai Medical heart in Los Angeles is becoming a member of a trial learning the advantages of nanox AI aortic valve calcification measurement resolution which is presently below improvement. We not too long ago carried out an on website revaluation of of the mannequin throughout roughly 600 retrospective instances. The outcome exceeded our expectations with six instances over extreme classification recognized and roughly 100 instances exhibiting medical related findings. The CT Sinai workforce has additionally expressed curiosity in collaboration on scientific publication primarily based on these outcomes, we’re very happy to be partnering with Cidr Sinai, one of many nation’s premier medical establishments. General, we’re seeing development in nanox AI enterprise pushed by new clients, enlargement of present agreements and the combination of nanox Well being it. Through the quarter we accomplished the strategic acquisition of Vaso Healthcare IT now nanox Well being it, a Healthcare IT supplier serving hospitals and healthcare system throughout the US with experience in Healthcare IT implementation. Since finishing the acquisition, we have now been progressing with integration and alignment whereas additionally signing a number of new buyer agreements. We’re seeing development pushed by new clients, enlargement of present agreements and the combination of our Well being IT capabilities and we count on this enterprise contribute to income from day one. Along with rising our footprint in AI, the Well being IT platform improve our skill to combine into medical workflow, broaden buyer instances, entry and help cross engagement throughout our ecosystems. Furthermore, the remainder of the group is leveraging the Well being IT workforce’s experience and market presence, significantly because it pertains to steer era for the usarad nanox AI and nanox arc. Much like our regulatory work, medical validation stays central to our technique and help our business efforts, producing proof throughout a number of purposes and supporting the usage of nanox options. I’ve already talked about that Pseudostina Medical heart is becoming a member of a trial of nanox AI Arctic Valve Calcification Measurement resolution and we have now achieved way more not too long ago. In an thrilling replace from our collaboration with MDS Wellness, an impartial supplier of wellness screening applications positioned in Michigan, we secured our first Institutional Evaluation Board approval for a medical trial throughout the us. The trial will deal with a lung most cancers screening of excessive danger sufferers and the applicability of NanoXR expertise because it pertains to affected person inhabitants of nano MDs. As I acknowledged earlier, we attended the European Convention of Radiology, the ECR the place we had been capable of current a number of scientific achievements and I would wish to share some highlights now. Dr. Noga Shabchin, AHRQ’s chief medical officer, introduced our scientific work on lung most cancers screening utilizing the nanox arc. Within the work with our collaboration in what was proven that’s the majority of sufferers, the screening outcomes primarily based on the lung ROG class, the usual lung most cancers screening calcification system was related when analyzing the CT and digital thrombosynthesis. This additional strengthens the applicability of the DTS as a possible addition to screening actions, ramping up globally. Dr. Reit Winfeimer, senior Medical and Medical Advisor, introduced the confirmed worth of our opportunistic screening for CT pictures utilizing Nanox AI3 SDA clear algorithm enabling earlier detection of power illness. Our newest imaging addition, Tomosynthesis augmented projection often called TEP2D was additionally featured in a number of scientific posters exhibiting the worth of TEP2D picture as a supplemental picture to DTS in lieu of the normal 2D x ray imaging with no extra dose or acquisition time inflicted on the affected person. And as well as, on the not too long ago concluded World convention of osteoporosis, NanoX AI bone resolution had been featured, together with updates from our ADAPT trial carried out throughout 4 NHS Belief and led by the College of Oxford, in addition to preliminary remark from our collaboration with the Greek Air Drive. The information will present as soon as extra the medical and financial advantages of AI primarily based opportunistic screening for routine CT exams. The validation summary evaluating the accuracy of the CCS 2.2 in contrast with cardiology knowledgeable reader as a part of AI Knowledgeable trial was anticipated as a poster on the Society of Cardiovascular Laptop Tomatography annual scientific assembly within the coming July. Outdoors of the US we’re enthusiastic about our current collaboration with Meir Medical heart in Israel which is a part of the Cliff, the Israel’s largest well being companies group, the place we have now an thrilling relationship. The nanox ARC has been deployed within the emergency division and will probably be utilized by orthopedic employees as a part of the medical workflow to assist set up the digital tomography as an efficient device with decrease dose and extra environment friendly workflow than immediately’s TT primarily based workflow. That is the primary time that nanox R is put in inside an emergency division in a significant hospital and signify confidence our collaboration has in nanos options. I am going to now present an replace on our sturdy OEM relationship. NANOS proceed to advance its expertise pipeline with ongoing improvement of subsequent era subject emission x ray sources and tube structure. Latest progress contains enchancment in an emitter design and fabrication processes aimed to extending chip lifetime and enhancing efficiency, improvement of micro focus and multi zone emitter configuration for purposes akin to semiconductor inspection and Helvet XRF and proceed development of the Nanox MDX, the multi supply two platform enabling new system structure for 3D imaging. The corporate can be progressing in a number of OEM collaboration and pilot tasks throughout industrial semiconductor and and safety market supporting the extension of nanox expertise into new purposes. We not too long ago obtained a purchase order order from a number one semiconductor tools producer for developmental emitters supporting superior inspection purposes at the forefront of subsequent era IC applied sciences with Oakrete Nationwide Laboratories, a U.S. authorities company. A second spherical of prototype is presently in progress and in course of with preparations underway as required supplies grow to be out there in parallel. One world imaging element provider has agreed to guage our Micro Focus beginner expertise and is making ready devoted check infrastructure to help that work. One other main OEM continues to advance prototype improvement primarily based on our emitter design, with validation actions ongoing. General, these engagements replicate continued momentum throughout a number of improvement tracks as we work to validate our expertise with established trade companions. Earlier than I transfer on, I would wish to briefly observe that regardless of the present geopolitical scenario within the Center east, we have now not skilled any materials disruption to our operation and our enterprise continues to function as deliberate. With that, I am going to flip the decision over to RAN to assessment our financials. RAN over to you. Thanks.

Erez we reported a GAAP internet loss for the fourth quarter of 2025 was $33.4 million, which is the reported interval, in contrast with a internet lack of $14.1 million within the fourth quarter of 2024, which is the comparable interval. The rise was largely attributable to an impairment of lengthy lived property within the quantity of $17.5 million, which was recorded throughout the reported interval because of the corporate’s restructuring plan that’s meant to higher align the corporate’s manufacturing actions. The rise was additionally attributable to a rise of $0.7 million within the gross loss, enhance of $1.1 million within the gross sales and advertising and marketing bills, and enhance of $1.4 million in different bills. Income for the reported interval was $3.7 million in comparison with income of $3.0 million within the comparable interval. The rise of $0.7 million enhance of 23% within the revenues stems from a rise of $0.3 million in our income from the teleradiology companies and a rise of $0.4 million in our income as a result of consolidations of Nano X Well being IT Inc. for the reason that completion of its acquisition on November 19, 2025. Gross loss for the reported interval was $3.6 million on a GAAP foundation in comparison with a GROSS lack of $2.9 million within the comparable interval on a GAAP foundation. Non GAAP gross loss for the reported interval was $1.2 million as in comparison with a gross lack of $0.3 million within the comparable interval, which represents a gross loss margin of roughly.32 on a non GAAP foundation for the reported interval as in comparison with a GROSS Loss margin of 9% on a non GAAP foundation within the comparable interval. Income from the teleradiology companies for the reported interval was $3.1 million in comparison with income of $2.8 million within the comparable interval. The corporate’s GAAP gross revenue from the teleradiology companies for the reported interval was $0.9 million. Gross revenue margins of roughly 27% in comparison with $0.6 million. Gross revenue margin of roughly 21% within the comparable interval. Non GAAP gross revenue of the corporate’s teleradiology companies for the reported interval was $1.5 million. Gross revenue margins of roughly 48% in comparison with a non GAAP gross revenue of $1.1 million. Gross revenue margin of roughly 41% within the comparable interval. The rise within the firm’s income and gross revenue from the teleradiology companies was primarily attributable to buyer retention, elevated hint and elevated quantity of the corporate’s studying companies throughout the reported interval. The corporate generated income by way of the gross sales and deployment of its imaging techniques which amounted to $49,000 for the reported interval with a gross lack of $2.6 million on a GAAP and non GAAP foundation in comparison with a income of $136,000 with a gross lack of $1.5 million on a GAAP and non GAAP foundation within the comparable interval. The income stems from the deployment of our Nano SALC techniques and and the gross sales of our OEM companies within the U.S. the corporate’s income from its AI and software program options for the reported interval was $0.5 million on a GAAP and non GAAP foundation in comparison with income of $0.1 million on a GAAP and non GAAP foundation within the comparable interval. Included within the reported interval income of $0.4 million which was generated by Nanox Elf IT Inc. Because the completion of its acquisitions on November 19, 2025. The Firm’s gross loss from its AI and software program options for the reported interval was $1.9 million on a GAAP foundation in comparison with a GROSS Lack of $2.0 million on a GAAP foundation within the comparable interval. Non GAAP gross revenue of the corporate’s AI and software program options for the reported interval was $0.1 million in comparison with $6,000 within the comparable interval. Analysis and improvement bills internet for the reported interval had been $4.8 million in comparison with $5.4 million within the comparable interval which represents a lower of $0.6 million. The lower was primarily attributable to a lower of $0.2 million in shared primarily based compensation, $0.6 million in grants obtained internet and $0.4 million in bills associated to our analysis and improvement actions to keep up our present and future product. The lower was mitigated by a rise of $0.5 million in salaries and wages, gross sales and advertising and marketing bills for the reported interval had been $2.0 million in comparison with $0.9 million within the comparable interval which represents a rise of $1.1 million primarily attributable to a rise of $0.7 million in salaries and wages attributable to our elevated efforts to commercializations of the commercializations of our merchandise within the US market and $0.4 million in gross sales and advertising and marketing actions primarily attributable to bills which are associated to the RSNA convention which happened throughout the fourth quarter of 2025. Common and administrative bills for the reported interval had been $6.0 million in comparison with $5.8 million within the comparable interval that the rise of $0.2 million was primarily attributable to bills which are associated to the acquisitions of Nanox Well being IT Inc. Different bills internet for the reported interval had been $1.4 million largely as a result of non money settlement with the shareholder. Just lately we initiated a restructuring plan that’s meant to higher align on restructuring and overhead price construction and to help gross revenue margin enchancment to the Firm’s long run monetary mannequin and the Firm’s strategic priorities. As a part of this restructuring plan, the Firm will shift its manufacturing operations from the corporate owned services into a completely outsourced mannequin. The plan will cut back structuring and overhead price by downsizing the restructuring services positioned within the firm’s 5 hub in South Korea and switch the manufacturing to different worldwide producers such because the Swiss chip maker cisem. The restructuring plan is predicted to be largely accomplished in fiscal 12 months 2026 and resulted with the Firm recording a non money impairment of its lengthy lived property of roughly $17.5 billion in fiscal 12 months of 2025, a value that’s associated to the impairment of its equipment and tools of the Firm’s chip manufacturing line. We proceed to guage the general compositions of the restructuring associated expenses together with potential more money parts. The remaining restructuring associated prices, if any, are anticipated to be incurred over the course of the implementation of the restructuring plan. The estimates of the entire expenses and the timing thereof are topic to quite a few assumptions and uncertainties and precise outcomes might differ materially. Non GAAP internet loss attributable to strange shares for the reported interval was $11.2 million in comparison with $10 million within the comparable interval. The rise of $1.2 million within the non GAAP internet loss attributable to strange shares was primarily attributable to a rise of 0.2 0.9 million within the non GAAP gross loss and the rise of 1.4 million within the non GAAP working bills. Please consult with the non GAAP changes which had been included within the monetary portion of the PR that we have now issued immediately. Turning to our steadiness sheet, as of December 31, 2025, we had money money equivalents and marketable securities of roughly $60 million in comparison with 55 $0.5 million as of September 30, 2025. We additionally had a 3.1 million quick time period mortgage from a financial institution. As of December 31, 2025, we ended the quarter with a property and tools internet of $29.7 million in comparison with $45.4 million as of December 31, 2024. The the lower was primarily attributable to an impairment of roughly $17.5 million that was recorded within the reported interval. Because of the above talked about impairment associated to the equipment and tools of the corporate’s Korean Fab, we had roughly 69.6 and 63.8 million shares excellent as of December 31, 2025 and December 31, 2020 respectively. Through the fourth quarter of 2025, the Firm offered roughly 4.2 million strange shares which generated internet proceeds of roughly $15.5 billion internet of issuance bills. With that, I’ll hand the decision again over to Erez.

Thanks Ron earlier than closing, I would like to handle the Management replace. After 5 years with the corporate, our nice Chief Monetary Officer Ron Daniels determined to step down from his function to discover different alternatives. Throughout his tenure, Ron performed an vital function in strengthening our monetary self-discipline, supporting our transition to a public firm and constructing the monetary and reporting infrastructure wanted to help our long run technique. He additionally led profitable capital raises that strengthened our steadiness sheet. Along with main our finance group, Ron additionally oversaw our investor relations exercise and labored carefully with traders and analysts all through his tenure. We’re grateful for his many contributions and need him continued success in his future endeavors. One will stay with the corporate to help a easy transition interval as we glance forward. We’re happy to announce that Man Nettensome will probably be becoming a member of Nano X Imaging as Chief Monetary Officer. Man brings intensive monetary management expertise with the US Publicly traded corporations together with a number of Senior CFO and CEO roles within the medtech corporations in addition to his deep expertise supporting development scale and world operations. His background contains capital elevating capital markets, each promote facet and purchase facet M and A and world monetary operations. Man additionally brings deep medical expertise management expertise with senior CFO and COOs at a number of med tech corporations during times of commercialization, scale up and world enlargement. Man additionally brings medical expertise expertise having served in theater management function during times of commercialization and enlargement. He is beforehand served as a CFO of Scopio Labs medical expertise firm creating AI primarily based diagnostic platform and most not too long ago was CFO of Valenc Semiconductor and New York Inventory Trade listed firm. We’re happy to welcome Man to the management workforce. He’ll be part of the corporate and can assume the function of Chief Monetary officer as of August 1st. As we glance again to this quarter and forward to the remainder of 2026, I wish to go away you with a couple of takeaways that underscore the momentum we’re constructing at Nano First. Our business progress in the US has been good. We’ve established a robust basis with varied companions anticipated to put techniques over the following two to a few years, together with important agreements with our industries Imperial Imaging, Integrity Imaging and others. This represents a elementary shift in how we’re poised to scale our enterprise from offering our expertise to deploying in a significant quantity, shifting towards a rising capex portion. That is what we imagine will get us nearer to our indicated revenues of 2026. Second, our strategic acquisition of Vaso Healthcare IT, now working as Nanox Well being IT, has instantly strengthened our capabilities and income base. The popularity we obtained at RSMA and ecr, together with the Newcomer Award at hdr, replicate the broader fact. Nanox is now acknowledged as a reputable participant contributing to dialog across the future customary of care within the medical imaging. That notion shifts in translating into deeper market engagement and sturdy pipeline. The muse we have now constructed positions us effectively to transform our pipeline into revenues and ship on our development aims. We’re enthusiastic about what lies forward and stay dedicated to executing on our imaginative and prescient of democratizing medical imaging globally. Thanks all to your continued help and we look ahead to updating you on our progress within the quarters forward. Operators, please open the decision for questions.

within the U.S. okay so we have now within the U.S. what we name Nano X Influence. We’ve 5 direct salespeople with the Director of the Nationwide Gross sales that’s coming from one of many greatest distributors within the nation with a variety of expertise. As well as we have now what we name the medical training specialist, the place their function and task is to go to the locations that we have now techniques put in, practice the folks attempting to get higher understanding of the referring doctor who works with this website. So their job is to construct consciousness across the website and what is the medical worth that may be added for different referring physicians that can try this. We’ve a couple of administration and operational tasks, together with tech people who find themselves doing the a part of the installations. And as well as we’re. We’ve people who find themselves doing the sdr like constructing the deal move. We’re within the technique of including one other two individuals who will probably be liable for the channel administration. Proper now, since we have now virtually 10 enterprise companions, one in all them is, as talked about immediately, is large. It will require a variety of coordination, a variety of help. We’ve an onboarding course of for every one in all them which could be very methodical that we do within the course of once we signal an settlement, the coaching course of, the demo unit, for instance, with a couple of of the enterprise companions that we these days signed, we have now tens of conferences that already had been organized with the potential clients with the intention to broaden and to meet what they’re dedicated to on this settlement.

In addition to the impairment bills we recorded in 2025, which was the impairment of primarily no matter is expounded to a budget line within the Korean Fab, which was amounted to $17.5 million within the non money expense. We do anticipate comparatively minor bills that are associated to extra effectivity steps that we will enact. It will not be. We do not anticipate it is going to be a big quantity of {dollars}. In order that’s truly going to in all probability to be a money expense. However as I mentioned, it isn’t going to be materials. Keep in mind that this FAB was constructed throughout COVID when semiconductors weren’t essentially out there. So proper now we’re rationalizing the scenario the place we have now a sustainable provider with a a lot decrease price of the chips that we do. However the FAB in Korea will probably be transformed to extra of R and D heart for the ceramic tubes that we’re creating there and may be even one other product that’s going to return out from this area.

Scott, a lot of the agreements had been signed starting of a couple of month or two after the RSNA and a part of them additionally after the ECR and most of them, a lot of the enterprise companions settlement that are going to shift our revenues to be extra coming from. Extra from CapEx slightly than solely the MSAs have been signed in the previous few weeks, as an instance a month. So proper now what we’ll do, we’ll begin the onboarding the method and the ramp up will probably be hopefully exponential in direction of as Ron mentioned, in direction of the second a part of the 12 months.

Nicely, what occurred within the. You imply should you have a look at the non gaap, in fact, which provides on the impairment bills and the opposite expense that primarily associated to the settlement with the shareholder, you see a rise in gna, which is I’d name it a seasonal enhance primarily due to audit and all sort of different period objects and bills that had been associated to the acquisition of Vaso Healthcare, which is one time in nature. On the opposite finish you additionally see a rise within the gross sales of promoting, that are a few of it’s associated to the commercialization efforts within the US market. In order that’s truly one thing that isn’t one time merchandise in nature however on the opposite finish. And if we’ll take part once more within the RSNA convention? That basically depends upon the query. So we participated within the RSNA within the fourth quarter, as you bear in mind, that price cash sadly. But when we take part once more, so then it is going to be recurring if you’d like. It will not.

Disclaimer: This transcript is supplied for informational functions solely. Whereas we try for accuracy, there could also be errors or omissions on this automated transcription. For official firm statements and monetary data, please consult with the corporate’s SEC filings and official press releases. Company contributors’ and analysts’ statements replicate their views as of the date of this name and are topic to vary with out discover.